NASDAQ:ABMD - ABIOMED Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ABIOMED, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $158.80 -6.49 (-3.93 %) (As of 02/25/2020 04:00 PM ET) Add Compare Today's Range$157.89Now: $158.80▼$167.0050-Day Range$164.80MA: $179.30▼$196.0152-Week Range$155.02Now: $158.80▼$352.87Volume680,873 shsAverage Volume974,734 shsMarket Capitalization$7.16 billionP/E Ratio29.85Dividend YieldN/ABeta0.46 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ABMD Previous Symbol CUSIP00365410 CIK815094 Webhttp://www.abiomed.com/ Phone978-646-1400Debt Debt-to-Equity RatioN/A Current Ratio5.04 Quick Ratio4.32Price-To-Earnings Trailing P/E Ratio29.85 Forward P/E Ratio38.54 P/E Growth1.68 Sales & Book Value Annual Sales$769.43 million Price / Sales9.30 Cash Flow$3.81 per share Price / Cash Flow41.71 Book Value$20.78 per share Price / Book7.64Profitability EPS (Most Recent Fiscal Year)$3.60 Net Income$259.02 million Net Margins29.14% Return on Equity19.53% Return on Assets17.26%Miscellaneous Employees1,371 Outstanding Shares45,063,000Market Cap$7.16 billion Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive ABMD News and Ratings via Email Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ABMD Rates by TradingView ABIOMED (NASDAQ:ABMD) Frequently Asked Questions What is ABIOMED's stock symbol? ABIOMED trades on the NASDAQ under the ticker symbol "ABMD." How were ABIOMED's earnings last quarter? ABIOMED, Inc. (NASDAQ:ABMD) issued its quarterly earnings data on Thursday, February, 6th. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.42. The medical equipment provider earned $221.60 million during the quarter, compared to analysts' expectations of $226.92 million. ABIOMED had a return on equity of 19.53% and a net margin of 29.14%. ABIOMED's revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.97 earnings per share. View ABIOMED's Earnings History. When is ABIOMED's next earnings date? ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for ABIOMED. What guidance has ABIOMED issued on next quarter's earnings? ABIOMED issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, February, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $846-877 million, compared to the consensus revenue estimate of $885.43 million. What price target have analysts set for ABMD? 7 brokers have issued 1-year price objectives for ABIOMED's stock. Their forecasts range from $165.00 to $340.00. On average, they anticipate ABIOMED's stock price to reach $248.33 in the next twelve months. This suggests a possible upside of 56.4% from the stock's current price. View Analyst Price Targets for ABIOMED. What is the consensus analysts' recommendation for ABIOMED? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ABIOMED. What are Wall Street analysts saying about ABIOMED stock? Here are some recent quotes from research analysts about ABIOMED stock: 1. According to Zacks Investment Research, "ABIOMED wrapped up fourth-quarter fiscal 2019 on a mixed note. Competition in the MedTech industry is intense. Pricing pressure and foreign currency headwinds persist. ABIOMED has underperformed the industry in a year’s time. However, the company continues to gain from its flagship Impella, which saw a strong quarter. Impella’s patient success stories and increasing global adoption are added positives. Revenues from Japan also skyrocketed in the quarter. Considerable expansion in the operating margin buoys optimism. Meanwhile, surging R&D expenses show increasing focus on innovation. In fact, the company continues to invest in training and education. The recent CE Mark of the Impella Connect is encouraging as well. The company’s balance sheet is debt-free." (5/8/2019) 2. BTIG Research analysts commented, "Term; Trimming PT to $340 From $400 Abiomed missed estimates in the quarter, delivering sales of $207M, short of consensus’ $219M forecast. Most of the weakness was U.S. driven, due to a weak cath lab (also seen in peer results) and to a greater extent, mix disruption leading to mgmt’s disproportionate focus away from protected PCI/elective procedures. To reflect these pressures, mgmt’s initial FY20 outlook calls for revenue growth of 17-23%, 6% below what mgmt (and we) would’ve considered more likely (and exactly the exact magnitude of the FQ4 shortfall). Mgmt outlined a number of initiatives to address these issues and noted that April is reportedly promising. The fact that mgmt still remains confident in addressable market and has left room to revise guidance during its next earnings call suggest there is good chance of upside." (5/7/2019) Has ABIOMED been receiving favorable news coverage? News coverage about ABMD stock has been trending very negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ABIOMED earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for ABIOMED. Are investors shorting ABIOMED? ABIOMED saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 4,020,000 shares, a drop of 6.9% from the January 15th total of 4,320,000 shares. Based on an average trading volume of 894,000 shares, the short-interest ratio is currently 4.5 days. Approximately 9.1% of the shares of the stock are short sold. View ABIOMED's Current Options Chain. Who are some of ABIOMED's key competitors? Some companies that are related to ABIOMED include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR). What other stocks do shareholders of ABIOMED own? Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Arista Networks (ANET), Align Technology (ALGN), Netflix (NFLX), Square (SQ), bluebird bio (BLUE), Adobe (ADBE) and Paypal (PYPL). Who are ABIOMED's key executives? ABIOMED's management team includes the folowing people: Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)Dr. David M. Weber, Chief Operating Officer (Age 58)Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)Mr. William J. Bolt, Exec. Officer (Age 67)Mr. Ian McLeod, VP & Corp. Controller Who are ABIOMED's major shareholders? ABIOMED's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (6.04%), Sands Capital Management LLC (5.42%), Renaissance Technologies LLC (5.16%), State Street Corp (4.56%), Alliancebernstein L.P. (2.11%) and Geode Capital Management LLC (1.58%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Institutional Ownership Trends for ABIOMED. Which institutional investors are selling ABIOMED stock? ABMD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Amundi Pioneer Asset Management Inc., Victory Capital Management Inc., Victory Capital Management Inc., Standard Life Aberdeen plc, Baird Financial Group Inc., Villere ST Denis J & Co. LLC and William Blair Investment Management LLC. Company insiders that have sold ABIOMED company stock in the last year include David M Weber and Martin P Sutter. View Insider Buying and Selling for ABIOMED. Which institutional investors are buying ABIOMED stock? ABMD stock was bought by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Alliancebernstein L.P., Credit Suisse AG, Jackson Square Partners LLC, Renaissance Technologies LLC, Bessemer Group Inc., Global Thematic Partners LLC and State Street Corp. View Insider Buying and Selling for ABIOMED. How do I buy shares of ABIOMED? Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is ABIOMED's stock price today? One share of ABMD stock can currently be purchased for approximately $158.80. How big of a company is ABIOMED? ABIOMED has a market capitalization of $7.16 billion and generates $769.43 million in revenue each year. The medical equipment provider earns $259.02 million in net income (profit) each year or $3.60 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe.View Additional Information About ABIOMED. What is ABIOMED's official website? The official website for ABIOMED is http://www.abiomed.com/. How can I contact ABIOMED? ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected] MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 503 (Vote Outperform)Underperform Votes: 453 (Vote Underperform)Total Votes: 956MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/25/2020 by MarketBeat.com StaffFeatured Article: What is an overbought condition?
